肝癌患者经导管动脉化疗栓塞后发生栓塞综合征的影响因素分析

Analysis of influencing factors of embolism syndrome in liver cancer patients after transcatheter arterial chemoembolization

目的探讨肝癌患者经导管动脉化疗栓塞(TACE)后发生栓塞综合征的影响因素。方法根据是否发生栓塞综合征将120例行TACE治疗的肝癌患者分为未发生组(n=63)和发生组(n=57)。比较两组患者的临床特征,采用Logistic回归模型分析肝癌患者TACE治疗后发生栓塞综合征的影响因素。结果发生组和未发生组患者的性别、心脏病病史、美国东部肿瘤协作组(ECOG)体力状况(PS)评分比较,差异均有统计学意义(P﹤0.05)。发生组和未发生组患者的年龄、体重指数、肿瘤数目、肿瘤直径、文化程度、高血压/糖尿病病史、术前疼痛情况、甲胎蛋白水平、Child-Pugh分级、巴塞罗那分期比较,差异均无统计学意义(P﹥0.05)。多因素Logistic回归分析结果显示,女性是肝癌患者TACE治疗后发生栓塞综合征的独立保护因素(P﹤0.05),有心脏病病史、ECOG PS评分为1分均是肝癌患者TACE治疗后发生栓塞综合征的独立危险因素(P﹤0.05)。结论性别、心脏病病史、ECOG PS均是肝癌患者TACE治疗后发生栓塞综合征的影响因素,临床应考虑上述因素,制订针对性的预防措施,从而改善患者预后。

Objective To explore the influencing factors of embolism syndrome in liver cancer patients after transcatheter arterial chemoembolization(TACE).Method A total of 120 liver cancer patients who received TACE were divided into non-occurrence group(n=63)and occurrence group(n=57)according to occurrence of embolism syndrome.The clinical characteristics of the two groups were compared,and the influencing factors of embolism syndrome in liver cancer patients after TACE were analyzed by Logistic regression model.Result There were significant differences in gender,history of heart disease and Eastern Cooperative Oncology Group(ECOG)performance status(PS)score between occurrence group and non-occurrence group(P<0.05).There were no significant differences in age,body mass index,tumor number,tumor diameter,degree of education,history of hypertension/diabetes,preoperative pain,α-fetoprotein level,Child-Pugh grade and Barcelona stage between the two groups(P>0.05).Multivariate Logistic regression analysis showed that female was protective factor for the occurrence of embolism syndrome in liver cancer patients after TACE(P<0.05),while history of heart disease and ECOG PS score of 1 point were risk factors for the occurrence of embolism syndrome in liver cancer patients after TACE(P<0.05).Conclusion Gender,history of heart disease and ECOG PS score are influencing factors of embolism syndrome in liver cancer patients after TACE.The above factors should be considered in clinic to formulate targeted preventive measures,so as to improve the prognosis of patients.